SG/CALL/ABBVIE/220/0.1/19.09.25 Stock

Warrant

DE000SU95PV9

Market Closed - Bid/Ask 03:48:31 2024-05-21 am EDT After market 02:00:05 pm
0.23 EUR -8.00% Intraday chart for SG/CALL/ABBVIE/220/0.1/19.09.25 0.22 -4.35%
Current month+13.64%
1 month-28.57%
Date Price Change
24-05-21 0.23 -8.00%
24-05-20 0.25 +8.70%
24-05-17 0.23 0.00%
24-05-16 0.23 +9.52%
24-05-15 0.21 +5.00%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 03:48 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SU95PV
ISINDE000SU95PV9
Date issued 2024-03-01
Strike 220 $
Maturity 2025-09-19 (486 Days)
Parity 10 : 1
Emission price 0.72
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.81
Lowest since issue 0.2
Delta0.13x
Omega 9.180
Premium36.79x
Gearing68.1x
Moneyness 0.7390
Difference Strike 57.35 $
Difference Strike %+26.07%
Spread 0.02
Spread %8.70%
Theoretical value 0.2200
Implied Volatility 20.42 %
Total Loss Probability 90.54 %
Intrinsic value 0.000000
Present value 0.2200
Break even 222.39 €
Theta-0.01x
Vega0.04x
Rho0.02x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
164.6 USD
Average target price
182.3 USD
Spread / Average Target
+10.76%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW